FDA give Novartis’ breast cancer treatment breakthrough status
Novartis’ CDK4/6 inhibitor Kisqali has acquired Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer. The FDA awarded the designation for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase